本文選題：參仙升脈口服液 + 緩慢性心律失常�。� 參考：《遼寧中醫(yī)藥大學(xué)》2016年碩士論文

【摘要】：目的:系統(tǒng)評(píng)價(jià)治療緩慢性心律失常的臨床有效性和安全性,為臨床治療提供循證依據(jù)。方法:計(jì)算機(jī)檢索CNKI相關(guān)期刊論文、萬方數(shù)據(jù)庫、重慶維普數(shù)據(jù)庫、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫等收集自2011-2016年參仙升脈口服液(治療組)相比其他藥物(對(duì)照組)治療緩慢性心律失常的RCT試驗(yàn),實(shí)驗(yàn)由兩名專業(yè)人員依據(jù)納入和排除標(biāo)準(zhǔn)獨(dú)立評(píng)價(jià)文獻(xiàn)質(zhì)量,提取資料后交叉核對(duì),采用Rev Man 5.33統(tǒng)計(jì)軟件進(jìn)行Meta分析。評(píng)價(jià)指標(biāo):臨床療效、平均心率、不良反應(yīng)等。結(jié)果:共納入16項(xiàng)RCT,合計(jì)1078例患者。與對(duì)照組比較,(1)15篇文獻(xiàn)比較了參仙升脈口服液與對(duì)照組的臨床療效:各研究間無統(tǒng)計(jì)學(xué)異質(zhì)性(P=0.98,I2=0%),應(yīng)用固定效應(yīng)模型進(jìn)行分析。結(jié)果顯示:[OR合并=4.55,95%CI(3.10,6.68),P0.00001],提示參仙升脈口服液組臨床療效優(yōu)于對(duì)照組。(2)14篇文獻(xiàn)比較了參仙升脈口服液與對(duì)照組平均心率的提高情況,各研究間有統(tǒng)計(jì)學(xué)異質(zhì)性(P0.00001,I2=93%),采用隨機(jī)效應(yīng)模型分析,結(jié)果顯示:[MD=5.81,95%CI(3.72,7.90),P0.00001],提示參仙升脈口服液組平均心率的提高幅度優(yōu)于對(duì)照組;(3)9篇文獻(xiàn)比較了參仙升脈口服液與對(duì)照組的不良事件發(fā)生率情況,各研究間有統(tǒng)計(jì)學(xué)異質(zhì)性(P=0.0005,I2=71%),采用隨機(jī)效應(yīng)模型分析。結(jié)果提示:[OR=0.20,95%CI(0.06,0.67),P=0.09),參仙升脈組不良反應(yīng)事件發(fā)生率小于對(duì)照組。結(jié)論:目前的數(shù)據(jù)表明參仙升脈口服液的臨床療效、平均心率的提高均優(yōu)于其他藥物,服用參仙升脈口服液組不良反應(yīng)小于對(duì)照組。但限于納入研究文獻(xiàn)的局限性,尚需更多高質(zhì)量的隨機(jī)對(duì)照試驗(yàn)予以證實(shí)。
[Abstract]:Objective: to evaluate the clinical efficacy and safety of the treatment of bradyarrhythmia and provide evidence-based basis for clinical treatment. Methods: CNKI Chinese periodical full-text database, Wanfang database, Chongqing Weipu database were searched by computer. The RCT test of Shenxianshengmai oral liquid (treatment group) in treating bradyarrhythmia compared with other drugs (control group) was collected from the Chinese Biomedical Literature Database from 2011 to 2016. The quality of literature was evaluated by two professionals according to the inclusion and exclusion criteria. The data were extracted and cross-checked, and Meta-analysis was carried out with Rev Man 5.33 statistical software. Evaluation measures: clinical efficacy, mean heart rate, adverse reactions and so on. Results: a total of 16 RCTs were included in 1078 patients. Compared with the control group, (1) the clinical efficacy of Shenxian Shengmai Oral liquid was compared with that of the control group. There was no statistical heterogeneity between the two groups (P < 0. 98%), and the fixed effect model was used to analyze it. The results showed that: [OR combined with 4.55.95 CI (3.106.68) P 0.00001] suggested that the clinical efficacy of Shenxian Shengmai oral liquid group was better than that of control group. (2) the increase of mean heart rate of Shenxian Shengmai oral liquid was compared with that of control group in 14 articles. There was statistical heterogeneity among the studies (P 0.00001). The random effect model was used to analyze the heterogeneity between the two studies. The results showed that the mean heart rate in Shenxian Shengmai oral liquid group was better than that in control group, and the incidence of adverse events in Shenxian Shengmai oral liquid was compared with that in control group. There was statistical heterogeneity among the studies (P < 0.0005 / I _ 2H _ (71%), and the random effect model was used to analyze it. The results suggested that the incidence of adverse events in the Shenxian Shengmai group was lower than that in the control group. Conclusion: the current data show that Shenxian Shengmai oral liquid has better clinical efficacy and average heart rate than other drugs, and the adverse reaction of Shenxian Shengmai oral liquid group is smaller than that of control group. However, limited to the limitations of the research literature, more high-quality randomized controlled trials are needed to confirm it.
【學(xué)位授予單位】：遼寧中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李沛;曾麗;;參仙升脈口服液治療心動(dòng)過緩性心律失常療效觀察[J];中西醫(yī)結(jié)合心腦血管病雜志;2011年09期

2 盧露;顧建成;張曉紅;趙濤;;參仙升脈口服液對(duì)自發(fā)性高血壓大鼠左室重構(gòu)和肌漿網(wǎng)鈣泵的影響[J];陜西中醫(yī);2012年06期

3 蔣秀焰;陳崇澤;;參仙升脈口服液致肝損傷1例[J];西北藥學(xué)雜志;2014年03期

4 王樹山;;參仙升脈口服液治療低血壓伴心動(dòng)過緩的臨床研究[J];中國實(shí)用醫(yī)藥;2013年23期

5 王強(qiáng);高軼峰;宋其海;;參仙升脈口服液與寧心寶膠囊治療心動(dòng)過緩的臨床觀察[J];中國醫(yī)藥導(dǎo)刊;2010年08期

6 胡建華;陳世健;華小麗;;參仙升脈口服液治療病態(tài)竇房結(jié)綜合征竇性心動(dòng)過緩的臨床研究[J];中成藥;2012年01期

7 高曉慧;李永紅;;參仙升脈口服液治療竇性心動(dòng)過緩32例臨床分析[J];中國實(shí)用醫(yī)藥;2011年25期

8 宋震;;舒喘靈聯(lián)合參仙升脈口服液治療竇性心動(dòng)過緩50例[J];中國中醫(yī)急癥;2011年09期

9 ;治療緩慢性心律失常的新藥——參仙升脈口服液[J];中國藥學(xué)雜志;2001年09期

10 郭曉麗;;參仙升脈口服液聯(lián)合阿托品治療心動(dòng)過緩性心律失常療效觀察[J];醫(yī)藥論壇雜志;2011年03期

相關(guān)會(huì)議論文 前2條

1 湯華;李健;黃智慧;;參仙升脈口服液治療病態(tài)竇房結(jié)綜合征療效觀察[A];第三屆全國中西醫(yī)結(jié)合心血管病中青年論壇暨新疆中西醫(yī)結(jié)合學(xué)會(huì)心血管專業(yè)委員會(huì)第二屆學(xué)術(shù)研討會(huì)論文匯編[C];2013年

2 武建偉;田梅;;參仙升脈口服液治療緩慢性心律失常48例[A];2013年全國醫(yī)藥學(xué)術(shù)交流會(huì)暨臨床藥學(xué)與藥學(xué)服務(wù)研究進(jìn)展培訓(xùn)班論文集[C];2013年

相關(guān)重要報(bào)紙文章 前4條

1 張麗蘭;步長(zhǎng)參仙升脈口服液上市[N];醫(yī)藥經(jīng)濟(jì)報(bào);2009年

2 駐京記者 李瑤;步長(zhǎng)又一心腦血管藥上市[N];醫(yī)藥經(jīng)濟(jì)報(bào);2009年

3 通訊員 吳楠;我市加快自主創(chuàng)新能力步伐[N];菏澤日?qǐng)?bào);2009年

4 通訊員 王鳳起 郜玉華;牡丹區(qū)著力推進(jìn)經(jīng)濟(jì)發(fā)展方式轉(zhuǎn)變[N];菏澤日?qǐng)?bào);2010年

相關(guān)碩士學(xué)位論文 前3條

1 張聰;參仙升脈口服液治療緩慢性心律失常療效與安全性的meta分析[D];遼寧中醫(yī)藥大學(xué);2016年

2 張斌;參仙升脈口服液對(duì)起搏患者起搏器壽命及工作安全性影響研究[D];遼寧中醫(yī)藥大學(xué);2016年

3 韓偉;參仙升脈口服液治療心腎陽虛、血瘀寒凝型房室傳導(dǎo)阻滯的臨床觀察[D];黑龍江中醫(yī)藥大學(xué);2010年

，

本文編號(hào)：2053545